Marex Group plc's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Marex Group plc reported revenue of $2.0B (+26.9% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY |
|---|---|---|
| Commission and fee income | $1.8B | $1.6B |
| Commission and fee expense | ($845.5M) | ($762.0M) |
| Net commission income/(expense) | $977.5M | $856.1M |
| Net trading income | $851.9M | $492.4M |
| Interest income | $912.8M | $765.2M |
| Interest expense | ($760.2M) | ($538.1M) |
| Net interest income | $152.6M | $227.1M |
| Net physical commodities income | $42.1M | $19.1M |
| Revenue | $2.0B | $1.6B |
| Compensation and benefits | ($1.2B) | ($971.1M) |
| Depreciation and amortisation | ($36.1M) | ($29.5M) |
| Other expenses | ($353.9M) | ($306.3M) |
| Total expenses | ($1.6B) | — |
| Impairment of goodwill | $0 | $0 |
| Net recovery of/(provision) for credit losses | $700.0K | $1.7M |
| Bargain purchase gain on acquisitions | $3.6M | $0 |
| Other income | $7.4M | $6.3M |
| Share of results in associates and joint ventures | $0 | $0 |
| Profit before tax from continuing operations | $411.6M | $295.8M |
| Tax | ($103.7M) | ($77.8M) |
| Profit after tax from continuing operations | $307.9M | — |
| Loss after tax from discontinued operations | ($200.0K) | — |
| Profit after tax | $307.7M | $218.0M |
| Ordinary shareholders of the Group | $293.9M | $204.7M |
| Non-controlling interest | $500.0K | $13.3M |
| Other equity holders | $13.3M | — |
| Basic (in dollars per share) | $4.12 | $2.96 |
| Diluted (in dollars per share) | $3.86 | $2.72 |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY |
|---|---|---|
| Goodwill | $237.4M | $176.5M |
| Intangible assets | $98.0M | $56.5M |
| Property, plant and equipment | $34.0M | $20.8M |
| Right of use asset | $76.9M | $59.9M |
| Investments | $28.5M | $24.0M |
| Trade and other receivables | $50.2M | — |
| Derivative instruments | $19.6M | — |
| Deferred tax | $30.6M | $46.7M |
| Treasury instruments (unpledged) | $83.1M | $53.5M |
| Treasury instruments (pledged as collateral) | $319.9M | $46.1M |
| Total non-current assets | $978.2M | $484.0M |
| Corporate income tax receivable | $27.6M | $12.5M |
| Trade and other receivables | $11.0B | $7.6B |
| Inventory | $483.7M | $35.8M |
| Financial assets (unpledged) | $602.9M | — |
| Financial assets (pledged as collateral) | $6.4B | — |
| Derivative instruments | $2.3B | $1.2B |
| Stock borrowing | $2.9B | $1.8B |
| Treasury instruments (unpledged) | $138.5M | $556.2M |
| Treasury instruments (pledged) and assets held under agreements to sell (repledged) | $3.5B | $2.9B |
| Reverse repurchase agreements | $3.1B | $2.5B |
| Cash and cash equivalents | $2.9B | $2.6B |
| Assets classified as held for sale | $357.4M | — |
| Total current assets | $33.7B | $23.8B |
| Total assets | $34.7B | $24.3B |
| Repurchase agreements | $4.1B | $2.3B |
| Trade and other payables | $13.0B | $9.7B |
| Stock lending | $5.5B | $5.0B |
| Short securities | $2.2B | $1.7B |
| Short term borrowings | $200.0M | $152.0M |
| Lease liability | $9.9M | $10.5M |
| Derivative instruments | $2.2B | $751.7M |
| Corporate tax | $8.5M | $41.9M |
| Debt securities | $3.4B | $2.1B |
| Provisions | $3.8M | $600.0K |
| Liabilities related to assets classified as held for sale | $294.8M | — |
| Total current liabilities | $31.0B | $21.8B |
| Lease liability | $87.4M | $67.0M |
| Derivative instruments | $19.4M | — |
| Debt securities | $2.3B | $1.5B |
| Deferred tax liability | $14.0M | $4.5M |
| Total non-current liabilities | $2.4B | $1.6B |
| Total liabilities | $33.4B | $23.3B |
| Total net assets | $1.3B | $976.9M |
| Share capital | $116.0K | $115.0K |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY |
|---|---|---|
| Profit before tax from continuing operations | $411.6M | $295.8M |
| Depreciation, amortization & impairment of property, plant & equipment, right-of-use asset and intangibles | $36.1M | — |
| Bargain purchase gain on acquisitions | ($3.6M) | $0 |
| Impairment of goodwill | $0 | $0 |
| Net recovery of/(provision) for credit losses | ($700.0K) | ($1.7M) |
| Share-based compensation expense | $43.5M | $29.6M |
| Share of results in associates and joint ventures | $0 | $0 |
| Other non-cash movements including exchange rate movements | ($49.7M) | $1.7M |
| Adjustments for decrease (increase) in trade and other receivables | ($2.6B) | ($2.8B) |
| Adjustments for increase (decrease) in trade and other payables | $2.3B | $3.0B |
| (Increase)/decrease in fixed income securities | $6.8M | ($11.0M) |
| (Increase) in treasury instruments | ($469.6M) | ($663.1M) |
| (Decrease)/Increase in net stock borrowing and lending | ($549.4M) | $3.3B |
| (Increase) in equity instruments | ($1.7B) | ($3.4B) |
| Increase/ (decrease) in net repurchase and reverse repurchase agreements | $1.2B | ($103.7M) |
| Net decrease/(increase) in derivative instruments | $469.3M | ($188.1M) |
| Net increase in debt securities | $2.1B | $1.4B |
| Adjustments For Increase (Decrease) In Borrowings | $27.8M | $152.0M |
| (Increase)/decrease in inventory | ($422.0M) | $127.6M |
| Corporation tax paid | ($140.9M) | ($58.1M) |
| Net cash inflow from operating activities | $667.5M | $1.2B |
| Redemption of investment in associate | $0 | $0 |
| Acquisition of businesses, net of cash acquired | ($241.6M) | ($11.0M) |
| Payment of contingent consideration | $0 | $0 |
| Purchase of investments | ($2.9M) | ($5.1M) |
| Proceeds from sale of investments | $0 | $700.0K |
| Purchase of intangible assets | ($6.7M) | ($8.2M) |
| Purchase of property, plant and equipment | ($13.1M) | ($11.7M) |
| Net cash used in investing activities | ($264.3M) | ($35.3M) |
| Proceeds from issuance of ordinary shares | 0 | 73.1M |
| Issuance costs of ordinary shares | 0 | -4.8M |
| Repayment of debt securities | ($6.3M) | $0 |
| Purchase of own shares | -44.1M | -19.8M |
| Dividends paid | ($55.5M) | ($77.1M) |
| Lease incentive received | $0 | $6.4M |
| Payment of lease liabilities | ($18.0M) | ($15.0M) |
| Net cash used in financing activities | ($123.9M) | ($37.2M) |
| Net increase in cash and cash equivalents including cash within assets held for sale | $279.3M | $1.1B |
| Less: Net increase in cash within assets held for sale | ($13.5M) | — |
| Net increase in cash and cash equivalents including cash within assets held for sale | $265.8M | — |
| Cash and cash equivalents at 1 January | $2.6B | $1.5B |
| Increase in cash | $265.8M | $1.1B |
| Effect of foreign exchange rate changes | $58.8M | ($17.9M) |
| Cash and cash equivalents at 31 December | $2.9B | $2.6B |
Marex Group plc score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.